Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Retained Earnings (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Retained Earnings for 16 consecutive years, with -$1.1 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 48.35% to -$1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 billion through Dec 2025, down 48.35% year-over-year, with the annual reading at -$1.1 billion for FY2025, 48.35% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.1 billion at Myriad Genetics, down from -$100000.0 in the prior quarter.
  • The five-year high for Retained Earnings was -$100000.0 in Q3 2025, with the low at -$1.1 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$282.5 million, with a median of -$8.2 million recorded in 2022.
  • Peak annual rise in Retained Earnings hit 99.99% in 2025, while the deepest fall reached 27085.0% in 2025.
  • Over 5 years, Retained Earnings stood at -$254.2 million in 2021, then plummeted by 44.06% to -$366.2 million in 2022, then plummeted by 71.9% to -$629.5 million in 2023, then decreased by 20.22% to -$756.8 million in 2024, then crashed by 48.35% to -$1.1 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.1 billion, -$100000.0, and -$1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.